Breaking News

Repligen Acquires Refine’s Bioprocessing Business

Gains Alternating Tangential Flow (ATF) System

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Repligen Corp. has acquired Refine Technology’s bioprocessing business for a combination of $20.5 million in cash and shares of Repligen stock, as well as potential milestones of as much as $8.8 million through 2016, and a royalty provision of as much as $2.2 million.   The acquisition includes Refine’s Alternating Tangential Flow (ATF) System, a device used to increase product yield during the fermentation step of the biomanufacturing process, which adds a profitable product line and expands th...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters